ELARA 24-Week Data Show Improvements in Wet AMD and DME

Data presented for the first time at AAO 2025 highlight vision gains and reduced retinal thickness in previously treated eyes using flexible aflibercept 8 mg dosing.

By: Diana V. Do, MD

Retinal Physician October 20, 2025

5 Key Takeaways

1

The ELARA study presents 24-week data on flexible aflibercept 8 mg dosing for wet AMD and DME.
2

Patients initially received monthly aflibercept 8 mg for 7 months before switching to a treat-and-extend protocol.
3

Vision gains of up to 3 letters were observed in both wet AMD and diabetic macular edema cohorts.
4

Retinal thickness reduced by approximately 32 µm in AMD and up to 50 µm in DME after treatment.
5

The study highlights promising outcomes despite patients having prior anti-VEGF treatment and ongoing disease activity.

Diana V. Do, MD

Retina Specialist

Specialties: Ophthalmology

Bio: Diana V. Do, MD, is a retina specialist and author for Retinal Physician. Her work focuses on ophthalmology and retinal disease, with interest in clinical trials, practice management, and emerging therapies for retinal conditions. In her Retinal Physician column, Dr. Do discusses developments in retina care, including clinical research collaboration, international clinical trial infrastructure, and investigational treatments for neovascular age-related macular degeneration and diabetic macular edema. She has also referenced her training connections with the Wilmer Eye Institute.

PentaVision

Retinal Physician

ELARA 24-Week Data Show Improvements in Wet AMD and DME

5 Key Takeaways

1

2

3

4

5

Recommendations